LANN-study: Lantus, Amaryl, Novorapid, Novomix Study

Diabetic patients failing on maximal oral treatment usually switch to twice daily administration of a mixture of short- and longacting insulin. Although this improves glycemic control, it is generally accompanied by a substantial gain in body weight. This may lead to an increase in body fat resulting in a worsening of insulin resistance, leading to an increase in insulin dose needed to maintain glycemic control.

The combination of glimepiride(amaryl) and short-acting insulin (novorapid) is thought to attain glycemic control with a smaller increase in body weight.

In this randomized controlled trial, 150 diabetics failing on maximal oral treatment will be randomized to preprandial use of Novorapid combined with Amaryl at 20.00 hours, twice daily Novomix 30, or once daily Lantus. Metformin will be continued.

In the year after randomisation, patients will be followed for glycemic control, body weight, body composition, recorded number of hypoglycemic events, plasma lipid levels, basal and stimulated C-peptide levels and adverse effects.

Inclusion criteria

• failing maximal oral treatment, defined as mean fasting blood glucose over 8 mmol/l and HbA1C over 7.5% for three months or more
• BMI 25 - 35 kg/m2
• fasting plasma C-peptide level over 0.3 nmol/l
• stable metformin and sulfonylurea dose for at least three months
• stable weight for at least three months (change maximal 2 kg)

Exclusion criteria

• fasting glucose over 25 mmol/l
• use of alpha-glucosidase inhibitors or thiazolidinediones in the two months preceding the study
• renal or liver failure defined as serum creatinine over 150 micromol/l, liver enzymes over 1.5 upper normal limit
• heart failure
• pregnancy
• alcohol more than two units per day
• inflammatory or infectious diseases
• unstable chronic disease
• discontinuation of smoking within three months of randomisation date
• allergy for or intolerance of glimepiride or novorapid.